Clinical Trial Update: ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial called ECLECTIC, evaluating EstroTEP and circulating biomarkers for ER-positive, HER2-negative metastatic breast cancer, is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Institut Curie | Conditions: Breast Carcinoma | Phase 3 | Status: RECRUITING